THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [8.4] ID: TIP-MED-000132

Cefixime Trihydrate

Active Ingredient / Scientific Identity: Cefixime Trihydrate • Class: Third-Generation Oral Cephalosporin Beta-Lactam Antibiotic (Bactericidal; WHO 'Watch' Group)

⚖️ Compare Profile
Generic / Entity NameCefixime Trihydrate ([8.4])
Verified Indian Brands / RefTaxim-O (Alkem), Zifi (FDC), Mahacef (Mankind)
Pharmacological ClassThird-Generation Oral Cephalosporin Beta-Lactam Antibiotic (Bactericidal; WHO 'Watch' Grou
Available Dosage FormsOral Film-Coated / Dispersible Tablets: 100 mg, 200 mg, 400 mg; Paediatric Dry Syrup: 50 mg/5 mL, 100 mg/5 mL
Regulatory ClassificationSchedule H1 Prescription Drug (Mandatory 3-Year Red-Border Register Retention) • NLEM
Key Warning & Review DateNo adjustment required.
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H1 Prescription Drug (Mandatory 3-Year Red-✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Cefixime Trihydrate (TIP-MED-000132, Reference Code [8.4]) is classified under Antimicrobials — Antibacterial & Antibiotic Agents (Ch 08) as a Third-Generation Oral Cephalosporin Beta-Lactam Antibiotic (Bactericidal; WHO 'Watch' Group). Within the Indian regulatory and compendial framework, it is governed under Schedule H1 Prescription Drug (Mandatory 3-Year Red-Border Register Retention) • NLEM 2022.

Verified Indian Market Examples / Compendial Status:
Taxim-O (Alkem), Zifi (FDC), Mahacef (Mankind)
Representative Indian Market Examples (Edition 2.7 Ch 08 [8.4], p. 94): Taxim-O (Alkem), Zifi (FDC Ltd), Mahacef (Mankind), Cefspan (GSK), Omnatax-O, Extacef — Strengths & Forms: Oral Film-Coated / Dispersible Tablets: 100 mg, 200 mg, 400 mg; Paediatric Dry Syrup: 50 mg/5 mL, 100 mg/5 mL
Dosage Forms & Available Strengths:
Oral Film-Coated / Dispersible Tablets: 100 mg, 200 mg, 400 mg; Paediatric Dry Syrup: 50 mg/5 mL, 100 mg/5 mL
Routes: Oral / Parenteral / Topical as specified by formulation

3. Mechanism of Action & Pharmacodynamics

Binds with high affinity to bacterial Penicillin-Binding Proteins (predominantly PBP3 and PBP1a/1b) in Gram-negative Enterobacterales and streptococci, acylating the transpeptidase active site, inhibiting peptidoglycan cross-linking, and inducing filamentous cell elongation followed by bactericidal osmotic lysis. Stable against many plasmid-mediated TEM-1/SHV-1 beta-lactamases (hydrolysed by ESBL and AmpC).

4. Therapeutic Indications & Evidence-Supported Uses

  • Uncomplicated enteric fever (Salmonella Typhi / Paratyphi) and oral step-down after IV Ceftriaxone
  • Acute uncomplicated urinary tract infections, pyelonephritis step-down, and acute otitis media / bacterial pharyngitis
  • Uncomplicated gonococcal urethritis/cervicitis (when Ceftriaxone IM is unavailable)

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Adults: 200 mg orally every 12 hours or 400 mg once daily. Enteric Fever: 20 mg/kg/day (up to 400 mg twice daily) for 10–14 days.

Administration & Meal Timing: Oral; with or without food (taking with food reduces GI upset without lowering overall absorption).

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Metabolism & Biotransformation:
No adjustment required.
Elimination & Renal Adjustment:
Reduce dose to 75% (300 mg/day) when CrCl is 21–60 mL/min, and to 50% (200 mg once daily) when CrCl < 20 mL/min or on haemodialysis.
Hepatic Impairment Considerations:
No adjustment required.

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • Immediate IgE-mediated anaphylaxis or severe cutaneous adverse reaction (SJS/TEN) to any Cephalosporin or Penicillin

Key Clinical Precautions: No adjustment required.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Diarrhoea and loose stools (10%–15%), abdominal pain, dyspepsia
  • Hypersensitivity reactions (maculopapular rash, urticaria, rare anaphylaxis)
  • Clostridioides difficile-associated diarrhoea (CDAD)
Serious / Dose-Limiting Adverse Effects:
  • Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • Warfarin: Cephalosporins reduce vitamin K-producing gut flora and may increase INR
  • Carbamazepine: Cefixime may elevate Carbamazepine plasma concentrations
  • Live Oral Typhoid Vaccine (Ty21a): delay vaccine by >=72 hours after stopping antibiotic

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.

Pharmacist Patient Counselling Points:

  • GOVERNANCE NOTE: Cefixime is a Schedule H1 antibiotic under the Drugs Rules 1945 — dispense only against a valid registered medical practitioner's prescription and log in the Schedule H1 register.
  • For paediatric dry syrup, reconstitute with boiled and cooled water up to the ring mark, shake well before each dose, and discard unused suspension after 7–14 days.
  • Complete the full course even if fever subsides after 3–4 days.

Storage, Stability & Dispensing Safeguards: Store tablets below 25–30°C; keep reconstituted oral suspension below 25°C and use within 7–14 days.

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2026) • NLEM 2022 (MoHFW) • CDSCO Approved Prescribing Information

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.